Zero Candida Technologies Stock Price, News & Analysis

Zero Candida Technologies, Inc. (OTCQB: ZCTFF) is a publicly traded FemTech medical device company focused on women's health. The company is developing a SMART, tampon-like therapeutic device that uses artificial intelligence and therapeutic blue light at a precise wavelength and intensity to treat Candida fungus associated with Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. Zero Candida’s shares trade on the TSX Venture Exchange under the symbol ZCT, on the OTCQB Venture Market under ZCTFF, and on the Frankfurt Stock Exchange under 9L2.

According to the company, VVC affects a large majority of women worldwide, and recurrent cases, defined as four or more episodes per year, are increasingly resistant to existing drug treatments. Zero Candida states that the root cause of this condition remains poorly understood and inadequately addressed, and positions its technology as a non-drug alternative that combines hybrid medicine and technology-based diagnostics to support safer, personalized care.

Business focus and technology

Zero Candida describes itself as a FemTech medical device company "revolutionizing women's health" by targeting unmet needs in gynecology. Its core development program centers on a SMART, tampon-like device, identified as ZC-001 or ZC-01 in company disclosures, that integrates artificial intelligence with therapeutic blue light. The device is designed to deliver treatment at a precise wavelength and intensity aimed at effectively treating Candida fungus and VVC in a personalized, at-home setting.

The company reports that its technology has demonstrated a 99.999% success rate in proof-of-concept testing for Candida fungus. It also emphasizes the use of technology-based diagnostics and data to support individualized care protocols and improve access for underserved populations.

ZC-001 device and design features

Zero Candida has announced a design freeze and the start of prototype production for its ZC-001 therapeutic device. The company indicates that ZC-001 is the first AI-enabled therapeutic device it is developing that integrates blue light therapy, targeted drug delivery, and wireless diagnostics for the personalized treatment of VVC. The design freeze covers both the device and its SMART docking and charging case.

Based on the company’s disclosures, key design elements of the ZC-001 system include:

• A docking system intended to provide secure, automatic alignment for reliable charging, sterilization, and dosing accuracy.
• Wireless connectivity designed to enable encrypted data transfer for remote physician monitoring and AI-driven analytics.
• Light-guide indicators to discreetly communicate device and charging status for usability.
• Use of medical-grade materials to support comfort, hygiene, and long-term biocompatibility.
• A modular assembly approach to support scalable manufacturing and potential adaptability to future gynecologic applications, as described by the company.

The company states that ZC-001 is intended to offer advantages for both physicians and patients by enabling personalized, at-home treatment with real-time data transmission, with the goal of reducing the need for frequent doctor visits while supporting individualized care protocols.

Regulatory and clinical pathway

Zero Candida reports that it is pursuing a De Novo regulatory pathway for its device. The company has indicated that it is advancing pre-clinical validation and device refinement, and has referenced completion of a safety trial in large animals (sheep). It has also outlined plans related to preclinical results, laboratory validation studies, and pilot and targeted clinical trials in specific jurisdictions such as Israel and the United States, as part of its stated development timeline.

The company describes ongoing documentation and planning activities to support its regulatory strategy, alongside both business-to-business (B2B) and business-to-consumer (B2C) approaches. Zero Candida notes that regulators and policymakers are calling for safer, less drug-reliant healthcare therapies that are cost-effective for patients, and positions its technology as a non-drug alternative within this context.

Intellectual property and partnerships

Zero Candida reports that it is expanding its global patent portfolio for its VVC treatment technology. According to the company, it holds a full patent in South Africa and has patent applications filed in the United States, Brazil, and Europe. It also states that it has secured funding and partnerships with leading hospitals in Europe and Israel in support of its development and clinical plans.

The company highlights ongoing discussions with major U.S. hospitals and pharmaceutical companies, which it says reinforce both the clinical need and commercial potential of its technology. These relationships are presented as part of the company’s strategy to validate its device concept and prepare for future clinical and market activities.

Market context and focus on VVC

In its public communications, Zero Candida notes that VVC affects approximately 75% of women worldwide and that recurrent cases are increasingly resistant to existing antifungal drug treatments. The company cites projections that the VVC treatment market could exceed US$2 billion by 2030 or within the next several years, and frames its device as a response to antifungal resistance and diagnostic gaps highlighted by health authorities.

Zero Candida describes its approach as combining hybrid medicine with technology-based diagnostics to improve access for underserved populations and to modernize gynecologic care. The company emphasizes that it is focused on addressing what it characterizes as a critical unmet need in women’s health through AI-driven, non-drug therapy.

Public listings and corporate structure

Zero Candida Technologies, Inc. is headquartered in Vancouver, British Columbia, according to its news releases. The company completed a reverse merger acquisition of an entity referred to as ZC and subsequently listed its shares on the TSX Venture Exchange under the symbol ZCT. It later commenced trading on the Frankfurt Stock Exchange under the symbol 9L2 and on the OTCQB Venture Market under the symbol ZCTFF.

The company’s disclosures describe it as a development-stage entity that has not yet generated revenues, with its primary focus on research and development of the ZC-01/ZC-001 device and pre-clinical validation. Zero Candida’s financial statements and Management’s Discussion and Analysis are made available through Canadian regulatory platforms referenced in its news releases.

Position within FemTech and women’s health

Zero Candida consistently characterizes itself as a FemTech company "pioneering" solutions for women’s health, with a specific focus on gynecological conditions related to Candida fungus and VVC. Its strategy, as described in its public statements, centers on AI-enabled blue light therapy, device-based diagnostics, and remote data capabilities to support personalized treatment.

By focusing on a single, clearly defined indication and device platform, the company presents a targeted approach within the broader FemTech space. Its communications emphasize the combination of medical device engineering, artificial intelligence, and blue light therapy as the foundation of its business model.